We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Aureus Pharma Licenses AurSCOPE® GPCR to Serono
News

Aureus Pharma Licenses AurSCOPE® GPCR to Serono

Aureus Pharma Licenses AurSCOPE® GPCR to Serono
News

Aureus Pharma Licenses AurSCOPE® GPCR to Serono

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aureus Pharma Licenses AurSCOPE® GPCR to Serono"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Aureus Pharma has announced that Serono has become a customer of its AurSCOPE GPCR knowledge database.

In this multi-year agreement, scientists at Serono Pharmaceutical Research Institute in Geneva will have access to both the AurSCOPE knowledge database and AurQUEST, a web application designed to query Aureus’ knowledge bases.

AurSCOPE GPCR is comprised of detailed biological activity quantitative data from patents and journals form.

G-Protein Coupled Receptors are a major interest for the pharmaceutical industry as they are targets in a number of therapeutic areas including CNS, cardiovascular, metabolic disease, obesity, oncology and others.

"Aureus Pharma’s knowledgebase on GPCR will provide Serono researcher’s with high quality quantitative data which will complement our in-house experimental platform," commented Serono’s Dr. Serge Halazy, Head of Research, Switzerland.

"We are very pleased to have Serono join our growing list of customers in the pharmaceutical and biotechnology industry," said Dr. Andre Michel, CEO of Aureus Pharma.

"Having access to the high quality data in AurSCOPE GCPR will aid researchers in the discovery of new GPCR targeted drugs."

Advertisement